Shanghai Lymphoma Clinical Cohort
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 1,000
- 主要终点
- Progression Free Survival (PFS)
研究概览
简要总结
The aim of this study is to prospectively collect clinical information on patients with lymphoma, and to explore the best therapeutic strategies in the real-world population.
详细描述
Lymphoma is a common hematological malignancy. This study aims to prospectively collect clinical information on patients with lymphoma, including the distribution of involved sites, clinical and molecular characteristics of different lymphoma subtypes, clinical treatment protocols, and prognosis, to explore the best therapeutic strategies in the real-world population.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 16 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 16 years (including 16 years old).
- •Patients newly diagnosed with non-Hodgkin lymphoma
- •Patients who have received systematic clinical treatment.
- •Patients with measurable lesions, at least containing one effective evaluation of efficacy.
排除标准
- •Patients who only receive supportive treatment.
- •Patients who cannot obtain effective evaluation data of efficacy.
结局指标
主要结局
Progression Free Survival (PFS)
时间窗: Baseline up to data cut-off (up to approximately 1 year)
Progression-Free Survival (PFS) will be defined from the date of starting therapy and the date of disease progression, relapse or death from any cause.
次要结局
- Overall Survival (OS)(Baseline up to data cut-off (up to approximately 1 year))